Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]

NCT01145352

Last updated date
Study Location
Yokohama City University School of
Tokyo, , , Japan
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Juvenile Idiopathic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
5-16 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients in active polyarticular JIA (restricted to the case of lack of effect by other treatment) during enrollment period (2.5years).

- Patients receiving Enbrel for JIA as diagnosed by a qualified physician.

- Age 5 - 16 years

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients not administered ENBREL

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Juvenile Idiopathic ArthritisEnbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
NCT01145352
  1. Tokyo,
ALL GENDERS
5 Years+
years
MULTIPLE SITES
Juvenile Idiopathic ArthritisPharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
NCT01513902
  1. Minneapolis, Minnesota
  2. Minneapolis, Minnesota
  3. Cincinnati, Ohio
  4. Portland, Oregon
  5. Bad Bramstedt,
  6. Hamburg,
  7. St. Augustin,
  8. Krakow,
  9. Lodz,
  10. Piestany,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Juvenile Idiopathic ArthritisStudy Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
NCT00962741
  1. Westmead, Sydney, New South Wales
  2. Parkville, Melbourne, Victoria
  3. Brussels,
  4. Gent,
  5. Leuven,
  6. Barranquilla, Atlantico
  7. Bogota, Cundinamarca
  8. Bucaramanga, Santander
  9. Brno,
  10. Praha 2,
  11. Praha 2,
  12. Le Kremlin Bicetre,
  13. Paris Cedex 14,
  14. Paris,
  15. Berlin,
  16. Bremen,
  17. Hamburg,
  18. Hannover,
  19. St. Augustin,
  20. Budapest,
  21. Chieti,
  22. Riga,
  23. Riga,
  24. Vilnius,
  25. Mexico City,
  26. Utrecht,
  27. Oslo,
  28. Bydgoszcz,
  29. Krakow,
  30. Warszawa,
  31. Wroclaw,
  32. Moscow,
  33. Saint-Petersburg,
  34. Belgrade,
  35. Nis,
  36. Kosice,
  37. Piestany,
  38. Ljubljana,
  39. Esplugues de Llobregat, Barcelona
  40. Madrid,
  41. Madrid,
  42. Valencia,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Juvenile Idiopathic ArthritisEfficacy Study Of Tofacitinib In Pediatric JIA Population
NCT02592434
  1. Little Rock, Arkansas
  2. Little Rock, Arkansas
  3. Loma Linda, California
  4. Loma Linda, California
  5. Loma Linda, California
  6. Loma Linda, California
  7. Loma Linda, California
  8. Los Angeles, California
  9. San Bernardino, California
  10. San Diego, California
  11. San Diego, California
  12. San Diego, California
  13. San Diego, California
  14. Hartford, Connecticut
  15. Hartford, Connecticut
  16. Washington, District of Columbia
  17. Washington, District of Columbia
  18. Miami, Florida
  19. Atlanta, Georgia
  20. Atlanta, Georgia
  21. Atlanta, Georgia
  22. Augusta, Georgia
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Chicago, Illinois
  26. Indianapolis, Indiana
  27. Indianapolis, Indiana
  28. Boston, Massachusetts
  29. Minneapolis, Minnesota
  30. Minneapolis, Minnesota
  31. Hackensack, New Jersey
  32. Bronx, New York
  33. Bronx, New York
  34. Lake Success, New York
  35. New Hyde Park, New York
  36. New York, New York
  37. New York, New York
  38. Charlotte, North Carolina
  39. Charlotte, North Carolina
  40. Charlotte, North Carolina
  41. Cincinnati, Ohio
  42. Portland, Oregon
  43. Portland, Oregon
  44. Philadelphia, Pennsylvania
  45. Austin, Texas
  46. Austin, Texas
  47. Houston, Texas
  48. Houston, Texas
  49. Houston, Texas
  50. Houston, Texas
  51. Houston, Texas
  52. Salt Lake City, Utah
  53. Salt Lake City, Utah
  54. Seattle, Washington
  55. Westmead, New South Wales
  56. Parkville, Victoria
  57. Birmingham, WEST Midlands
  58. Bristol,
  59. Bristol,
  60. Madrid,
  61. Tolyatti,
  62. Saint-Petersburg,
  63. San Luis Potosi,
  64. Istanbul,
  65. Curitiba, Parana
  66. Moscow,
  67. Vancouver, British Columbia
  68. Vinnitsya,
  69. Calgary, Alberta
  70. Istanbul,
  71. Juiz de Fora, MG
  72. Haifa,
  73. San Luis Potosi,
  74. San Miguel de Tucuman, Tucuman
  75. Sao Paulo,
  76. Moscow,
  77. Montreal, Quebec
  78. Vancouver, British Columbia
  79. Kayseri,
  80. Ankara,
  81. Caba,
  82. Calgary, Alberta
  83. Bydgoszcz,
  84. San Luis Potosi,
  85. Kfar Saba,
  86. Rosario, Santa FE
  87. Istanbul,
  88. Guadalajara, Jalisco
  89. Valencia,
  90. Ivano-Frankivsk,
  91. Leuven,
  92. Salvador, Bahia
  93. Ramat Gan,
  94. Sao Paulo, SAN Paulo
  95. Moscow,
  96. San Luis Potosi,
  97. Montreal, Quebec
  98. Curitiba, Parana
  99. Botucatu, SAO Paulo
  100. Minneapolis, Minnesota
  101. Rio de Janeiro, RJ
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
Official Title Enbrel-JIA Use Results Survey [All-Case Surveillance]
Brief Summary

This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA.

  1. Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events
  2. Secondary Factors affecting safety and to confirm the efficacy such as DAS28.
Detailed Description All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
Condition Juvenile Idiopathic Arthritis
Intervention Drug: Etanercept (genetical recombination)
All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
Other Name: Enbrel
Study Groups/Cohorts Etanercept (genetical recombination)
All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
Intervention: Drug: Etanercept (genetical recombination)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 5, 2013)
113
Original Estimated Enrollment
 (submitted: June 15, 2010)
300
Actual Study Completion Date October 2013
Actual Primary Completion Date October 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients in active polyarticular JIA (restricted to the case of lack of effect by other treatment) during enrollment period (2.5years).
  • Patients receiving Enbrel for JIA as diagnosed by a qualified physician.
  • Age 5 - 16 years

Exclusion Criteria:

  • Patients not administered ENBREL
Sex/Gender
Sexes Eligible for Study:All
Ages 5 Years to 16 Years   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Japan
Removed Location Countries  
 
Administrative Information
NCT Number NCT01145352
Other Study ID Numbers 0881Y1-4689
B1801130
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2014